Ovid Therapeutics initiated Phase 1 dosing of OV4071, an oral KCC2 activator, and expanded OV329 development for pediatric epilepsy indications in Q1 2026. OV329 showed favorable safety and pharmacokinetics at higher doses, supporting Phase 2 trials for treatment-resistant seizures. The company raised $60 million in March 2026 and received $53.9 million from warrant exercises, boosting its cash to $165.6 million as of March 31, 2026, extending its runway into 2029. Ovid plans further clinical studies for OV329 and OV4071 targeting brain disorders including epilepsy and psychosis.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
